Daclizumab (Yttrium-90 radiolabeled anti-Tac)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Daclizumab (Yttrium-90 radiolabeled anti-Tac), covering 2008-03-04 to 2008-03-04. Get the full timeline:
Most recent: Clinical Trial Update: Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac [Phase 1]